The overall goal of this project is to develop novel compounds and approaches to image histone decatelylases (HDACs), key enzymes associated with epigenetic gene regulation. HDACs have been linked to the pathogenesis of cancer, and small-molecule HDAC inhibitors (HDACi) have been shown to have significant biological effects in preclinical models of cancer as well as in early clinical trials. Our group has recently developed class-specific and pan-HDACi based on rational ligand and substrate design, HDAC biochemistry, and on high-content screening (Nat Chem Biol 2009;6:238-243). Based on these developments, we will now address fundamental questions regarding HDAC biology and inhibition, such as: 1) What are the tissue distribution levels of HDACs in vivo? 2) Do cancer cells have different expression levels to stromal cells? 3) What are the activity levels of HDACs (not just abundance) in vivo? 4) What are HDAC activity levels at the whole organ level? 5) Can HDAC inhibition (using HDACi) be quantitated using imaging? The central hypothesis underlying this research is that novel imaging agents will allow us to both visualize the distribution of HDACs as well as quantitate their activity levels in vivo.
The specific aims are thus: 1) to develop and test small molecule HDAC ligands for imaging;2) to validate and test imaging agents in mouse models;and 3) to image HDAC expression and therapeutic efficacy of HDAC inhibition in ovarian cancer in vivo.

Public Health Relevance

Histone decatelylases (HDACs) have been linked to the pathogenesis of cancer, and small-molecule HDAC inhibitors (HDACi) have been shown to have significant biological effects in both preclinical models as well as in early clinical trials of cancer Thus, having the ability to image HDAC function in vivo in both normal and diseased tissue will likely have wide-ranging implications for both basic and applied biomedical research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Keliher, Edmund J; Klubnick, Jenna A; Reiner, Thomas et al. (2014) Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes. ChemMedChem 9:1368-73
Dubach, J Matthew; Vinegoni, Claudio; Weissleder, Ralph (2014) Steady state anisotropy two-photon microscopy resolves multiple, spectrally similar fluorophores, enabling in vivo multilabel imaging. Opt Lett 39:4482-5
Pittet, Mikael J; Nahrendorf, Matthias; Swirski, Filip K (2014) The journey from stem cell to macrophage. Ann N Y Acad Sci 1319:1-18
Thurber, Greg M; Reiner, Thomas; Yang, Katherine S et al. (2014) Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther 13:986-95
Courtis, Alexandra M; Santos, Sofia A; Guan, Yinghua et al. (2014) Monoalkoxy BODIPYs--a fluorophore class for bioimaging. Bioconjug Chem 25:1043-51
Hideshima, T; Mazitschek, R; Santo, L et al. (2014) Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28:457-60
Kim, Eunha; Yang, Katherine S; Giedt, Randy J et al. (2014) Red Si-rhodamine drug conjugates enable imaging in GFP cells. Chem Commun (Camb) 50:4504-7
Dubach, J M; Vinegoni, C; Mazitschek, R et al. (2014) In vivo imaging of specific drug-target binding at subcellular resolution. Nat Commun 5:3946
Turetsky, Anna; Kim, Eunha; Kohler, Rainer H et al. (2014) Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor. Sci Rep 4:4782
Aceto, Nicola; Bardia, Aditya; Miyamoto, David T et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110-22

Showing the most recent 10 out of 266 publications